Priscilla Guglielmo

Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: July 15, 2026

Non-FDG PET/CT.

Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

Published: May 21, 2026

Response assessment in [177Lu]PSMA: where do we stand?

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: May 14, 2026

Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 25, 2026

PSMA-avid Pleural Solitary Fibrous Tumor Incidentally Detected on [18F] Piflufolastat PSMA PET/CT.

Journal: Clinical nuclear medicine

Published: April 06, 2026

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

Journal: European journal of nuclear medicine and molecular imaging

Published: March 20, 2026

Novel radiopharmaceuticals for bladder cancer evaluation.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: March 19, 2026

From prostate to bladder cancer: current evidence and expanding horizons in nuclear medicine.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: March 19, 2026

Targeting Cytotoxic T-Cell Effector Function with Granzyme B PET: Translational Advances Toward Predicting Immunotherapy Outcomes.

Journal: Molecular diagnosis & therapy

Published: March 01, 2026

Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.

Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.

Non-FDG PET/CT.

Non-FDG PET/CT.

Response assessment in [177Lu]PSMA: where do we stand?

Response assessment in [177Lu]PSMA: where do we stand?

Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial.

Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial.

PSMA-avid Pleural Solitary Fibrous Tumor Incidentally Detected on [18F] Piflufolastat PSMA PET/CT.

PSMA-avid Pleural Solitary Fibrous Tumor Incidentally Detected on [18F] Piflufolastat PSMA PET/CT.

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review.

Novel radiopharmaceuticals for bladder cancer evaluation.

Novel radiopharmaceuticals for bladder cancer evaluation.

From prostate to bladder cancer: current evidence and expanding horizons in nuclear medicine.

From prostate to bladder cancer: current evidence and expanding horizons in nuclear medicine.

Targeting Cytotoxic T-Cell Effector Function with Granzyme B PET: Translational Advances Toward Predicting Immunotherapy Outcomes.

Targeting Cytotoxic T-Cell Effector Function with Granzyme B PET: Translational Advances Toward Predicting Immunotherapy Outcomes.

Comparing Response Evaluation Methods for PRRT in Neuroendocrine Tumors: Insights from an Exploratory Study.

Comparing Response Evaluation Methods for PRRT in Neuroendocrine Tumors: Insights from an Exploratory Study.

PET-CT radiomics for immunotherapy response.

PET-CT radiomics for immunotherapy response.

Is There a Role of FAPI Pet in Renal and Bladder Cancer?

Is There a Role of FAPI Pet in Renal and Bladder Cancer?